Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan
James L. Pool,Roland E. Schmieder,Michel Azizi,Jean-Claude Aldigier,Andrzej Januszewicz,Walter Zidek,Yanntong Chiang,Andrew Satlin +7 more
Reads0
Chats0
TLDR
Aliskiren monotherapy provides antihypertensive efficacy and placebo-like tolerability in patients with hypertension and aliskiren and valsartan in combination may provide additive BP-lowering effects with maintained tolerability.About:
This article is published in American Journal of Hypertension.The article was published on 2007-01-01 and is currently open access. It has received 214 citations till now. The article focuses on the topics: Aliskiren & Valsartan.read more
Citations
More filters
Journal ArticleDOI
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial
TL;DR: The combination of aliskiren and valsartan at maximum recommended doses provides significantly greater reductions in blood pressure than does monotherapy with either agent in patients with hypertension, with a tolerability profile similar to that with aliskirens and valartan alone.
Journal ArticleDOI
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance
Shawna A. Cooper,Adam Whaley-Connell,Javad Habibi,Yongzhong Wei,Guido Lastra,Camila Manrique,Sameer Stas,James R. Sowers +7 more
TL;DR: Currently understood mechanisms underlying the development of resistance to the metabolic actions of insulin in cardiovascular as well as skeletal muscle tissue are examined.
Journal ArticleDOI
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials
TL;DR: Although dual blockade of the renin-angiotensin system may have seemingly beneficial effects on certain surrogate endpoints, it failed to reduce mortality and was associated with an excessive risk of adverse events such as hyperkalaemia, hypotension, and renal failure compared with monotherapy.
Journal ArticleDOI
Redox Control of Renal Function and Hypertension
TL;DR: The imbalance of redox homeostasis within the kidney is integral in hypertension and the progression of kidney disease, and an emerging paradigm exists for renal redox contribution to hypertension.
Journal ArticleDOI
Aliskiren, the First Renin Inhibitor for Treating Hypertension: Reactive Renin Secretion May Limit Its Effectiveness
Jean E. Sealey,John H. Laragh +1 more
TL;DR: Until the possibility is eliminated of inducing increases in blood pressure with aliskiren in patients with highly reactive renin levels, it seems safe and simple to stick to the less expensive, equally effective and widely available generic CEI drugs for treating the renin factor in hypertension.
References
More filters
Journal ArticleDOI
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
Alan H. Gradman,Roland E. Schmieder,R. Lins,Juerg Nussberger,Yanntong Chiang,Martin P. Bedigian +5 more
TL;DR: Once-daily oral treatment with aliskiren lowers blood pressure effectively, with a safety and tolerability profile comparable to that of irbesartan and placebo, in patients with mild-to-moderate hypertension.
Journal ArticleDOI
Structure-based design of aliskiren, a novel orally effective renin inhibitor.
Jeanette Marjorie Wood,Jürgen Maibaum,Joseph Rahuel,Markus G. Grütter,N. C. Cohen,Vittorio Rasetti,Heinrich Rüger,Richard Dr. Göschke,Stefan Stutz,Walter Fuhrer,Walter Schilling,Pascal Rigollier,Yasuchika Yamaguchi,Frederic Cumin,Hans-Peter Baum,Christian Schnell,Peter Herold,Robert Mah,Chris Jensen,Eoin O'Brien,Alice Stanton,Martin P. Bedigian +21 more
TL;DR: Aliskiren is the first in a novel class of renin inhibitors with the potential for treatment of hypertension and related cardiovascular diseases and employs a combination of molecular modelling and crystallographic structure analysis to design renin inhibitor lacking the extended peptide-like backbone of earlier inhibitors.
Journal ArticleDOI
Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100) Comparison With Enalapril
TL;DR: Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.
Journal ArticleDOI
Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren
TL;DR: It is demonstrated that aliskiren, through inhibition of renin, is an effective and safe orally active BP-lowering agent and well tolerated at all doses studied.
Journal ArticleDOI
Valsartan. A review of its pharmacology and therapeutic use in essential hypertension.
Anthony Markham,Karen L. Goa +1 more
TL;DR: Valsartan is an effective treatment for mild to moderate essential hypertension and may be particularly useful in patients who experience persistent cough during ACE inhibitor therapy.